Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The LINQ II™ insertable cardiac monitoring system is the world's most accurate ICM,1-4 personalized for the patient's lifestyle and customized for the clinician's workflow. LINQ II ICM is ideal for patients experiencing infrequent symptoms that require long-term monitoring or ongoing management.
Download LINQ II BrochureMeet LINQ II
New enhanced TruRhythm™ algorithms, remote programming, and 4.5 years* longevity.5
* Nominal settings.
8x fewer false positives1-4
Disclaimer: A controlled, head-to-head study evaluating the comparative performance of these devices has not been done.
†Based on AF episodes ≥ 2 minutes and in known AF patients. % of false positives = (1 – episode PPV). AF episodes PPV may vary between gross and patient average.
‡Lux-Dx™ ICM, Confirm Rx™ with SharpSense™ technology & BIOMONITOR III have no published clinical evidence showing AF episode PPV or AF sensitivity.
1 Pürerfellner H, Sanders P, Sarkar S, et al. Adapting detection sensitivity based on evidence of irregular sinus arrhythmia to improve atrial fibrillation detection in insertable cardiac monitors. Europace. November 1, 2018;20(FI_3):f321-f328.
2 Confirm Rx™ ICM DM3500 FDA Clearance Letter. 2017.
3 Nölker G, Mayer J, Boldt LH, et al. Performance of an Implantable Cardiac Monitor to Detect Atrial Fibrillation: Results of the DETECT AF Study. J Cardiovasc Electrophysiol. December 2016;27(12):1403-1410.
4 BIOTRONIK BioMonitor 2 Technical Manual. 2017.
Reveal LINQ with
TruRhythm Detection Delivers§:
LINQ II with
TruRhythm Delivers||:
AF episode duration sensitivity used is ≥ 2 min.
§ Reveal LINQ with TruRhythm vs. Reveal LINQ.
|| LINQ II vs. Reveal LINQ with TruRhythm.
BlueSync technology within LINQ II ICM enables secure, wireless communication via Bluetooth® Low Energy without compromising device longevity.5
¶ Medtronic FocusOnSM Monitoring Service is provided by Medtronic Monitoring Inc., a wholly owned subsidiary of Medtronic.
# First European (TÜV notified body)-approved remote programmable device.
Secure communication from CareLink to patient monitor to device.
The Reveal LINQ Mobile Manager tablet app makes it possible to manage all of your workflow needs, including13:
33% Time
Savings for
Reviewing ICM Transmissions<sup>10</sup>
LINQ II ICM is projected to deliver efficiency gains for device clinics.
Fewer Alerts from New Algorithms and Nominal Settings
+
Elimination of
Manual Transmission
Over 200 Clinic Hours/Year Saved at clinics managing 200 ICMs14
Access interactive courses, videos, and educational resources to extend your learning on LINQ II ICM.
Visit Medtronic AcademyMedtronic, Medtronic logo, and Further, Together are trademarks of Medtronic. The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Medtronic is under license. ™Other third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. Apple and the Apple logo are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc.
Nominal settings.
Based on AF episodes ≥ 2 minutes and in known AF patients. % of false positives = (1 – episode PPV). AF episodes PPV may vary between gross and patient average.
Lux-Dx™ ICM, Confirm Rx™ with SharpSense™ technology, and BIOMONITOR III have no published clinical evidence showing AF episode PPV or AF sensitivity.
Reveal LINQ with TruRhythm vs. Reveal LINQ.
LINQ II vs. Reveal LINQ with TruRhythm.
Medtronic FocusOnSM Monitoring Service is provided by Medtronic Monitoring Inc., a wholly owned subsidiary of Medtronic.
First European (TÜV notified body)-approved remote programmable device.
Pürerfellner H, Sanders P, Sarkar S, et al. Adapting detection sensitivity based on evidence of irregular sinus arrhythmia to improve atrial fibrillation detection in insertable cardiac monitors. Europace. November 1, 2018;20(FI_3):f321-f328.
Confirm Rx™ ICM DM3500 FDA Clearance Letter. 2017.
Nölker G, Mayer J, Boldt LH, et al. Performance of an Implantable Cardiac Monitor to Detect Atrial Fibrillation: Results of the DETECT AF Study. J Cardiovasc Electrophysiol. December 2016;27(12):1403-1410.
BIOTRONIK BioMonitor 2 Technical Manual. 2017.
LINQ II™ LNQ22 ICM Clinician Manual. M974764A001D.
Medtronic data on file. 2019.
Penela D, Van Huls Van Taxis C, Aguinaga L, et al. Neurohormonal, structural, and functional recovery pattern after premature ventricular complex ablation is independent of structural heart disease status in patients with depressed left ventricular ejection fraction: a prospective multicenter study. J Am Coll Cardiol. September 24, 2013;62(13):1195-1202.
Penela D, Fernández-Armenta J, Aguinaga L, et al. Clinical recognition of pure premature ventricular complex-induced cardiomyopathy at presentation. Heart Rhythm. December 2017;14(12):1864-1870.
Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. January 22, 2013;61(3):e6-e75.
Alert Analysis for Reveal LINQ™ with TruRhythm™ and LINQ II™. Medtronic data on file. 2020.
Passman R, Rogers J, Sarkar S, et al. Development and validation of a dual sensing scheme to improve accuracy of bradycardia and pause detection in an insertable cardiac monitor. Heart Rhythm. 2017;14(7):1016-1023.
Van Heel L, Ousdigian K, Seiler A, Alfaro Vives C, Cheng Y-J, Rogers J. New Algorithms Reduce Clinician Review Burden and Maintain Diagnostic Yield for Repetitive ECGs in Insertable Cardiac Monitors. Circulation. November 11, 2019;140:A11830.
Reveal LINQ™ Mobile Manager 2.3 Online Help Instructions for Use.
Rosemas S. AF Algorithm Clinic Efficiency. Medtronic data on file. April 2020.